BR112023000338A2 - Composição farmacêutica compreendendo um derivado de diaminopirimidina ou sal farmaceuticamente aceitável do mesmo e processos para preparar a mesma - Google Patents
Composição farmacêutica compreendendo um derivado de diaminopirimidina ou sal farmaceuticamente aceitável do mesmo e processos para preparar a mesmaInfo
- Publication number
- BR112023000338A2 BR112023000338A2 BR112023000338A BR112023000338A BR112023000338A2 BR 112023000338 A2 BR112023000338 A2 BR 112023000338A2 BR 112023000338 A BR112023000338 A BR 112023000338A BR 112023000338 A BR112023000338 A BR 112023000338A BR 112023000338 A2 BR112023000338 A2 BR 112023000338A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparing
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO UM DERIVADO DE DIAMINOPIRIMIDINA OU SAL FARMACEUTICAMENTE ACEITÁVEL DO MESMO E PROCESSOS PARA PREPARAR A MESMA. A presente invenção fornece uma composição farmacêutica compreendendo (S)-N-(1-(2-((4-amino-3-nitrofenil)amino)-6-propilpirimidin-4-il)pirrolidin-3-il)acetamida ou um sal farmaceuticamente aceitável do mesmo que possui uma atividade como um agonista do receptor 5-HT4 e um agente acidificante; e um processo para preparar a mesma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200084595A KR20220006776A (ko) | 2020-07-09 | 2020-07-09 | 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법 |
PCT/KR2021/008327 WO2022010175A1 (en) | 2020-07-09 | 2021-07-01 | Pharmaceutical compositions comprising a diaminopyrimidine derivative or pharmaceutically acceptable salt thereof and processes for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023000338A2 true BR112023000338A2 (pt) | 2023-03-28 |
Family
ID=79552635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023000338A BR112023000338A2 (pt) | 2020-07-09 | 2021-07-01 | Composição farmacêutica compreendendo um derivado de diaminopirimidina ou sal farmaceuticamente aceitável do mesmo e processos para preparar a mesma |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230255967A1 (pt) |
EP (1) | EP4178550A4 (pt) |
JP (1) | JP2023534186A (pt) |
KR (1) | KR20220006776A (pt) |
CN (1) | CN116133649A (pt) |
AU (1) | AU2021305561A1 (pt) |
BR (1) | BR112023000338A2 (pt) |
CA (1) | CA3185116A1 (pt) |
MX (1) | MX2023000364A (pt) |
WO (1) | WO2022010175A1 (pt) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130035344A1 (en) * | 2009-12-29 | 2013-02-07 | Kowa Co., Ltd. | Pharmaceutical composition for oral administration |
WO2012115478A2 (en) * | 2011-02-25 | 2012-08-30 | Yuhan Corporation | Diaminopyrimidine derivatives and processes for the preparation thereof |
WO2013114389A1 (en) * | 2011-12-21 | 2013-08-08 | Mylan Laboratories Limited. | Process for preparing solid oral formulations comprising low dose of entecavir |
KR101832842B1 (ko) * | 2012-01-13 | 2018-02-27 | 한미약품 주식회사 | 안정성이 향상된 에페리손 또는 이의 약학적으로 허용 가능한 염 및 특정 산성화제를 포함하는 약학 조성물 |
AU2015246500B2 (en) * | 2014-04-14 | 2018-03-22 | National Institute Of Biological Sciences, Beijing | 5-HT2B Antagonists |
KR102293907B1 (ko) * | 2015-06-30 | 2021-08-26 | 한미약품 주식회사 | 이리노테칸 함유 경구용 고형제제 및 그 제조방법 |
CN107216319B (zh) * | 2016-03-21 | 2021-10-08 | 中国科学院上海药物研究所 | 一种2,4-二氨基嘧啶类衍生物、其制备方法及用途 |
DK3586832T3 (da) * | 2018-06-28 | 2021-04-06 | Synformulas Gmbh | Farmaceutisk sammensætning til behandlingen af forstoppelse |
-
2020
- 2020-07-09 KR KR1020200084595A patent/KR20220006776A/ko active Search and Examination
-
2021
- 2021-07-01 JP JP2023501418A patent/JP2023534186A/ja active Pending
- 2021-07-01 EP EP21836795.1A patent/EP4178550A4/en active Pending
- 2021-07-01 WO PCT/KR2021/008327 patent/WO2022010175A1/en active Application Filing
- 2021-07-01 MX MX2023000364A patent/MX2023000364A/es unknown
- 2021-07-01 AU AU2021305561A patent/AU2021305561A1/en active Pending
- 2021-07-01 US US18/014,262 patent/US20230255967A1/en active Pending
- 2021-07-01 CA CA3185116A patent/CA3185116A1/en active Pending
- 2021-07-01 CN CN202180048620.0A patent/CN116133649A/zh active Pending
- 2021-07-01 BR BR112023000338A patent/BR112023000338A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
US20230255967A1 (en) | 2023-08-17 |
WO2022010175A1 (en) | 2022-01-13 |
EP4178550A4 (en) | 2024-09-11 |
MX2023000364A (es) | 2023-02-27 |
EP4178550A1 (en) | 2023-05-17 |
CA3185116A1 (en) | 2022-01-13 |
KR20220006776A (ko) | 2022-01-18 |
CN116133649A (zh) | 2023-05-16 |
JP2023534186A (ja) | 2023-08-08 |
AU2021305561A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017393A2 (pt) | Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto | |
CL2008003789A1 (es) | Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer. | |
BR112022007612A2 (pt) | Inibidores de raf quinases | |
AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
CR7882A (es) | Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas | |
CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
PE20071184A1 (es) | Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo | |
BRPI0618479A2 (pt) | pirrolpiridinas composição farmacêutica que as contém | |
CR10573A (es) | Derivados del pirazol como inhibidores del citocromo p450 | |
BRPI0411699A (pt) | compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos | |
BR112018015389A2 (pt) | derivado de 5-etil-4-metil-pirazol-3-carboxamida tendo atividade como agonista de taar | |
RS52941B (en) | A COMBINATION OF ALFA 7 NICOTINE AGONISTS AND ANTIPSYCHOTICS | |
CL2008002622A1 (es) | 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno. | |
BR112017012396A2 (pt) | combinação farmacêutica que compreende um agonista seletivo do receptor s1p1 | |
BR112021026397A2 (pt) | Antagonista de ep2 | |
BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
BR112023019435A2 (pt) | Inibidores de nek7 | |
AR117655A1 (es) | Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal | |
CO5700753A2 (es) | Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad | |
MX2022004027A (es) | Farmaco farmaceutico que contiene derivado de heterocicliden acetamida. | |
AR062114A1 (es) | Moduladores de la actividad del receptor de quimiocina, formas cristalinas y procesos. | |
BR112022025012A2 (pt) | Inibidores de quinase de nek7 | |
BR112022024374A2 (pt) | Composições farmacêuticas de pralsetinibe | |
AR058047A1 (es) | Administracion de inhibidores de dipeptidil peptidasa | |
SV2005001805A (es) | 3-aminopirrolidinas como inhibidores de la captacion de monoamina ref. x-15735 |